Pharmacogenomics of Alzheimer’s disease and cerebral palsy: implications of the apolipoprotein E genotype

ISSN： 1479-6708

Source： Future Neurology, Vol.2, Iss.4, 2007-07, pp. : 353-356

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Apolipoprotein E-related neurotoxicity as a therapeutic target for Alzheimer’s disease

By Marques Marcos Crutcher Keith

Journal of Molecular Neuroscience, Vol. 20, Iss. 3, 2003-08 ,pp. : 327-337

Humana Press, Inc

Access to resources Recommend Favorite

Apolipoprotein E is a prime suspect, not just an accomplice, in Alzheimer’s disease

By Crutcher Keith

Journal of Molecular Neuroscience, Vol. 23, Iss. 3, 2004-10 ,pp. : 181-188

Humana Press, Inc

Access to resources Recommend Favorite

Insulin-degrading enzyme, apolipoprotein E, and Alzheimer’s disease

By Edland Steven

Journal of Molecular Neuroscience, Vol. 23, Iss. 3, 2004-10 ,pp. : 213-217

Humana Press, Inc

Access to resources Recommend Favorite

Apolipoprotein E4 as a target for developing new therapeutics for Alzheimer’s disease

By Refolo Lorenzo Fillit Howard

Journal of Molecular Neuroscience, Vol. 23, Iss. 3, 2004-10 ,pp. : 151-155

Humana Press, Inc

Access to resources Recommend Favorite

Lipid profile factors and apolipoprotein E polymorphism in Alzheimer’s disease

By Helisalmi Seppo

Future Neurology, Vol. 2, Iss. 1, 2007-01 ,pp. : 25-27

Future Medicine

Access to resources Recommend Favorite